AstraZeneca’s Phase I / II Covid-19 vaccine trial unlikely to report convincing protection data

In a 21 May media release, AstraZeneca has indicated it has secured total manufacturing capacity for one billion AZD1222 doses. Credit: Shutterstock.



  • astrazeneca covid-19 vaccine trial